Bertrand Cariou

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

Bertrand Cariou, Samy Hadjadj, Matthieu Wargny et al. · Diabetologia · 2020 · 842 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +12

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Evan A. Stein, Robert Dufour et al. · The Lancet · 2014 · 751 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice

Bertrand Cariou, Kirsten van Harmelen, Daniel Durán-Sandoval et al. · Journal of Biological Chemistry · 2006 · 541 citations · Full text

Life Sciences, Biochemistry, Endocrinology +17

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

J.‐F. Yale, George L. Bakris, Bertrand Cariou et al. · Diabetes Obesity and Metabolism · 2013 · 486 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

Vanita R. Aroda, Stephen C. Bain, Bertrand Cariou et al. · The Lancet Diabetes & Endocrinology · 2017 · 443 citations

Medicine, Endocrinology, Pharmacology +10